Managing the Adult Patient With Hereditary Angioedema: A Roundtable Discussion

Activity Description & Educational Objectives

In this activity, an expert panel discusses strategies for diagnosing and treating patients with hereditary angioedema (HAE), focusing on prophylactic and acute therapeutic approaches, available treatment options, and methods for improving quality of life in patients with this disease.

Upon completion of this activity, participants should be better able to:

• Apply evidence-based strategies to the differential diagnosis of HAE, with a focus on early clinical identification of this disease
• Summarize prophylactic and acute treatment strategies for the management of HAE, including the timing of preventative measures versus on-demand therapeutic decisions
• Evaluate mechanism of action, efficacy, and safety of available therapies to prevent and rapidly treat HAE attacks
• Employ methods to improve quality of life in patients with HAE, such as the development of individualized treatment regimens and providing increased access to therapy

Target Audience

This activity has been designed to meet the educational needs of allergists, clinical immunologists, primary care physicians, gastroenterologists, and other clinicians involved in the care of patients with hereditary angioedema.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: January 30, 2013 - January 29, 2014
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Jonathan A. Bernstein, MD
Professor of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section
Director of Clinical Research
University of Cincinnati College of Medicine
Cincinnati, Ohio

Jonathan A. Bernstein, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for CSL Behring; Dyax Corp.; Shire; and ViroPharma Incorporated.

Grant/Research Support from CSL Behring; Dyax Corp.; Pharming; Shire; and ViroPharma Incorporated.

Speakers Bureau participant with CSL Behring; Dyax Corp.; Shire; and ViroPharma Incorporated.

Other Financial or Material Support from co-editor of the Joint Taskforce on Practice Parameters on Angioedema.

Interviewee

William R. Lumry, MD
Clinical Professor of Internal Medicine/Allergy
University of Texas Southwestern Medical School
Medical Director
AARA Research Center
Dallas, Texas

William R. Lumry, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Alcon Laboratories, Inc.; CSL Behring; Dyax Corp.; Merck & Co., Inc.; Novartis Corporation; Shire HGT; and ViroPharma Incorporated.

Grant/Research Support from Apotex Corp.; Alcon Laboratories, Inc.; Biotest Pharmaceuticals Corporation; Boehringer Ingelheim; CSL Behring; Dyax Corp.; Genentech, Inc.; GlaxoSmithKline; Green Cross; Merck & Co., Inc.; National Institutes of Health; Novartis Corporation; Pharming; Roxanne; Shire HGT; Teva Pharmaceuticals; and ViroPharma Incorporated.

Speakers Bureau participant with Alcon Laboratories, Inc.; CSL Behring; Dyax Corp.; Merck & Co., Inc.; Novartis Corporation; Shire HGT; and ViroPharma Incorporated.

CME Reviewer

Timothy Craig, DO
Professor of Medicine and Pediatrics
Penn State College of Medicine
Hershey, Pennsylvania

Timothy Craig, DO, has a financial interest/relationship or affiliation in the form of:

Consultant for CSL Behring.

Grant/Research Support from CSL Behring; Dyax Corp.; Pharming Group NV; Shire; and ViroPharma Incorporated.

Speakers Bureau participant with CSL Behring; Dyax Corp.; Shire; and ViroPharma Incorporated.

Medical Director

Christopher Washburn, PhD
PVI, PeerView Institute for Medical Education

Christopher Washburn, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5251-13-T.

This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.